title: Baseline-transmitted V106V/I/M non-nucleoside reverse transcriptase inhibitor resistance in HIV-1 subtype B infection.
abstract: We report a case in which an antiretroviral therapy (ART)-naïve patient diagnosed with HIV-1 subtype B presented with baseline genotype and phenotype resistance tests, confirming a V106V/I/M nucleoside resistance mutation. The V106V/I/M mutation represents a mixture of virus strains conferring resistance to the non-nucleoside reverse transcriptase inhibitor antiretrovirals efavirenz and nevirapine. V106M mutation is not often observed as a primary resistance mutation in patients infected with HIV-1 subtype B. The patient responded well to an ART regimen consisting of tenofovir-emtricitabine and raltegravir, achieving and maintaining an undetectable HIV RNA.
authors.affiliation: Nova Southeastern University, Fort Lauderdale, Florida, USA. esherman@nova.edu
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Sherman
authors.forename: Shara
authors.initials: S
authors.lastname: Elrod
authors.forename: Paula
authors.initials: P
authors.lastname: Eckardt
mesh_terms: D000328:Adult; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D008297:Male; D009154:Mutation; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*
chemical_list: D018894:Reverse Transcriptase Inhibitors